Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$225K Buy
+4,300
New +$227K ﹤0.01% 3491
2024
Q2
Sell
-300,000
Closed -$12.9M 2091
2024
Q1
$12.9M Buy
+300,000
New +$12.4M 0.03% 622
2023
Q1
Sell
-700
Closed -$24.6K 2362
2022
Q4
$24.6K Sell
700
-2,450,000
-100% -$81.6M ﹤0.01% 1372
2022
Q3
$72.1M Buy
+2,450,700
New +$92.9M 0.29% 85
2022
Q1
Sell
-400,000
Closed -$22.1M 1253
2021
Q4
$22.1M Buy
+400,000
New +$20.8M 0.09% 313
2018
Q3
Sell
-200,000
Closed -$10.1M 1075
2018
Q2
$10.1M Buy
+200,000
New +$10.1M 0.04% 439

Other funds holding GSK

Steven Cohen's GSK Position: Q2 2026 in Review

Steven Cohen opened a new position in GSK (GSK) in Q2 2026: 2,652,881 shares worth $139M. The stake represents 0.15% of the portfolio and ranks #132 among its holdings. This is a return to the name: Steven Cohen previously reported a position in GSK as recently as Q4 2025.

Steven Cohen first reported a position in GSK in Q4 2015 and has held it in 17 quarters since. The position peaked at $227M in Q4 2022. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Steven Cohen held 2,652,881 shares of GSK worth $139M as of Q2 2026.
  • GSK was a new Steven Cohen position in Q2 2026.
  • GSK made up 0.15% of Steven Cohen's portfolio in Q2 2026, its #132 holding.
  • Steven Cohen first reported a position in GSK in Q4 2015 and has held it in 17 quarters since.
  • Steven Cohen's GSK position peaked at $227M in Q4 2022.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.